|
23 May 2022 |
Armata Pharmaceuticals Announces First Patient Dosed in Phase 1b/2a 'diSArm' Study of AP-SA02 in Adults with Bacteremia due to Staphylococcus aureus
|
|
23 May 2022 |
Seres Therapeutics Presents Phase Ill Results of SER-109 for Recurrent C. Difficile Infection at the Digestive Disease Week (DDW) Annual Meeting
|
|
20 May 2022 |
Athersys Announces That Its Partner, HEALIOS K.K., Reported Topline Data From the TREASURE MultiStem Ischemic Stroke Study
|
|
20 May 2022 |
Atara Biotherapeutics Provides Update on Strategic Collaboration with Bayer
|
|
19 May 2022 |
ReCode Therapeutics Presents New Preclinical Data from mRNA-based Program for Cystic Fibrosis at the ATS 2022 International Conference
|
|
18 May 2022 |
Veloxis Pharmaceuticals Announces Dosing of the First Participant in a Phase I Study of VEL-101, a Novel Investigational Drug for Kidney Transplant Immunosuppression
|
|
18 May 2022 |
XyloCor Therapeutics Announces Presentation of Preliminary Clinical Data from Phase 1 Portion of the EXACT Phase 1/2 Study of XC001 Novel Gene Therapy for Refractory Angina at AATS and ASGCT
|
|
18 May 2022 |
Adaptive Phage Therapeutics Announces First Patient Dosed in the DANCE Trial, a Phase 1/2 Study Evaluating APT Phage Bank in Diabetic Foot Osteomyelitis
|
|
18 May 2022 |
AviadoBio Presents Preclinical Data at ASGCT 2022 Demonstrating that AVB-101 Represents a Novel and Promising Approach to the Treatment of Frontotemporal Dementia
|
|
18 May 2022 |
Sernova and Evotec Enter into an Exclusive Global Strategic Partnership for iPSC-Based Beta Cell Replacement Therapy to Develop and Commercialize a ‘Functional Cure’ for Diabetes
|
|
18 May 2022 |
Ultragenyx Acquires Global Rights to AAV Gene Therapy ABO-102 for Sanfilippo Syndrome Type A (MPS IIIA) from Abeona Therapeutics
|
|
18 May 2022 |
Poseida Therapeutics Presents Encouraging Preclinical Data Highlighting P-ckit-ALLO1 at the ASGCT 2022 Annual Meeting
|
|
18 May 2022 |
AVROBIO Reports Positive Data From Phase 1/2 Clinical Trial of Investigational Gene Therapy for Cystinosis, Including New Interim Data on Neurocognitive Measures
|
|
18 May 2022 |
City of Hope and Imugene Announce First Patient Dosed in Phase 1 Trial to Test Cancer-Killing Oncolytic Virus Against Solid Tumors
|
|
18 May 2022 |
Lysogene Provides Clinical Update on AAVance Phase 2/3 Clinical Trial with Gene Therapy LYS-SAF302 for the Treatment of MPS IIIA at the 25th Annual ASGCT Meeting
|
|
17 May 2022 |
ASC Therapeutics Announces Podium and Poster Presentations of IND-Enabling Studies for ASC618, a Second-Generation Gene Therapy for Hemophilia A, at the 25th ASGCT Meeting, May 16-19, 2022 in Washington, D.C.
|
|
17 May 2022 |
Preclinical Proof-of-Concept Data Supporting Future Clinical Development of Two New Cell Therapies Being Presented by Adaptimmune at ASGCT
|
|
16 May 2022 |
Graphite Bio Presents Preclinical Gene Replacement Data for GPH102 for Beta-thalassemia at the ASGCT 25th Annual Meeting
|
|
16 May 2022 |
Jaguar Gene Therapy Presents Preclinical Data of JAG101 in Type 1 Galactosemia at American Society of Gene and Cell Therapy 25th Annual Meeting
|
|
16 May 2022 |
Catamaran Bio Presents Preclinical Data Supporting Novel Engineered CAR-NK Cell Therapies For Treating Solid Tumors
|
|
16 May 2022 |
ReCode Therapeutics Presents Preclinical Data from Inhaled mRNA Therapeutic Program in Primary Ciliary Dyskinesia (PCD) in Three Posters at the ATS 2022 International Conference
|
|
16 May 2022 |
Atamyo Therapeutics Announces Significant Milestones for ATA-100 and ATA-200, its Gene Therapy Programs to Treat Limb-Girdle Muscular Dystrophy 2I/R9 and 2C/R5
|
|
14 May 2022 |
Urovant Sciences® Presents Interim Data from Phase 2a Study of Investigational Novel Gene Therapy, URO-902, Supporting Safety, Tolerability, and Efficacy Endpoints at 2022 American Urological Association Meeting
|
|
13 May 2022 |
Caribou Biosciences Announces Positive Initial Data for CB-010 Anti-CD19 Allogeneic CAR-T Cell Therapy
|
|
11 May 2022 |
Myeloid Therapeutics Doses First Patient with MT-101 in the IMAGINE Phase 1/2 Clinical Study, Marking the First-ever Dosing of an mRNA Engineered CAR Monocyte to Humans
|
